将分子发现转化为动脉样硬化的新疗法
Daniel J Rader1, Alan Daugherty
1Cardiovascular Institute and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, 654 BRBII/III, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. rader@mail.med.upenn.edu
Nature
|February 22, 2008
概括
动脉样硬化,动脉壁的加厚,导致主要疾病. 向脂蛋白和宁- ангиотензин-阿尔多斯特系统显示了对动脉样硬化心血管疾病的治疗益处.
科学领域:
- 心血管科学 心血管科学
- 病理学 病理学 病理学
- 医学研究 医学研究
背景情况:
- 动脉样硬化,以动脉壁加厚为特征,是冠状动脉和脑血管疾病导致全球死亡的主要原因.
- 脂蛋白和氨酸- ангиотензин-阿尔多斯特系统与动脉样硬化心血管疾病的发病有关.
- 了解高血压,失脂症和糖尿病等危险因素对于治疗动脉样硬化至关重要.
研究的目的:
- 审查脂蛋白和氨酸- ангиотензин-阿尔多斯特系统在动脉样硬化中的作用.
- 探索主要风险因素对动脉样硬化疾病的贡献.
- 基于分子病原发生的新型治疗点的识别.
主要方法:
- 临床试验和研究研究的文献综述.
- 分析脂蛋白和氨酸- ангиотензин-阿尔多斯特系统的影响.
- 检查动脉样硬化斑块发展背后的分子机制.
主要成果:
- 临床试验证实了针对特定脂蛋白的好处.
- 针对宁- ангиотензин-阿尔多斯特系统的干预措施证明了有效性.
- 研究正在通过阐明分子病原性来发现新的治疗点.
结论:
- 向脂蛋白和宁- ангиотензин-阿尔多斯特系统为动脉样硬化心血管疾病提供了一个有前途的治疗策略.
- 对动脉样硬化和风险因素贡献的分子基础的进一步研究将产生新的治疗途径.
更多相关视频
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


